Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
29477797
DOI
10.1016/j.euf.2018.02.005
PII: S2405-4569(18)30033-6
Knihovny.cz E-resources
- MeSH
- Chemotherapy, Adjuvant MeSH
- Antigens, Neoplasm therapeutic use MeSH
- Cystectomy MeSH
- Double-Blind Method MeSH
- Immunotherapy * MeSH
- Neoplasm Invasiveness MeSH
- Clinical Trials, Phase II as Topic MeSH
- Humans MeSH
- Neoplasm Proteins therapeutic use MeSH
- Urinary Bladder Neoplasms drug therapy pathology surgery MeSH
- Early Termination of Clinical Trials MeSH
- Randomized Controlled Trials as Topic MeSH
- Recombinant Proteins therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antigens, Neoplasm MeSH
- MAGEA3 protein, human MeSH Browser
- Neoplasm Proteins MeSH
- Recombinant Proteins MeSH
The MAGNOLIA study, investigating the concept of perioperative immunotherapy in muscle- invasive bladder cancer, was prematurely terminated. The lessons learned that should be considered before initiating and conducting future clinical trials in this field are highlighted.
EAU Research Foundation Arnhem The Netherlands
Hôpital Edouard Herriot Lyon France
Hospital Motol Charles University Prague Czech Republic
Kiev Municipal Oncology Hospital Kiev Ukraine
Medical University Warsaw Warsaw Poland
Radboud University Medical Centre Nijmegen The Netherlands
Saint Petersburg State Pavlov Medical University St Petersburg Russia
Universitätsklinikum Köln Köln Germany
University of Medicine and Pharmacy Carol Davila Bucharest Romania
References provided by Crossref.org
